The CORIST part 3 dose finding study is progressing well and topline data are expected in the second half of January 2024
Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, is close to presenting topline data in the ongoing CORIST part 3 study. Final patient data is expected in the second half of January 2024 following which the results will be published. The topline data will therefore be delayed a few weeks compared to previously expected before year-end 2023.
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
The information was provided by the contact person above for publication on December 21, 2023, at 17.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.